Profile data is unavailable for this security.
About the company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-179.09m
- Incorporated1994
- Employees198.00
- LocationOmeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
- Phone+1 (206) 676-5000
- Fax+1 (206) 676-5005
- Websitehttps://www.omeros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc | 0.00 | -27.32m | 184.07m | 22.00 | -- | 3.71 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 184.47m | 1.00 | -- | 61.15 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 185.05m | 75.00 | -- | 2.55 | -- | 23.12 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Outlook Therapeutics Inc | 0.00 | -159.13m | 185.72m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 187.88m | 53.00 | 12.10 | 4.05 | 11.11 | 3.97 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 190.85m | 65.00 | -- | 3.91 | -- | 6.81 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 192.07m | 36.00 | 192.23 | 63.22 | 67.54 | 4.27 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Omeros Corp | 0.00 | -179.09m | 192.08m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 193.92m | 185.00 | 12.49 | 3.80 | 7.21 | 0.8557 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 194.05m | 101.00 | -- | 10.46 | -- | 7.16 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 195.26m | 51.00 | -- | 0.7452 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Scilex Holding Co | 47.05m | -160.60m | 195.69m | 106.00 | -- | -- | -- | 4.16 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| INmune Bio Inc | 131.00k | -34.50m | 200.79m | 11.00 | -- | 6.28 | -- | 1,532.76 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 203.79m | 128.00 | -- | 0.9669 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Data as of May 29 2024. Currency figures normalised to Omeros Corp's reporting currency: US Dollar USD
33.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 31 Mar 2024 | 4.70m | 8.11% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.86m | 6.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.17m | 5.47% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 1.91m | 3.30% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 1.68m | 2.90% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.38m | 2.38% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.24m | 2.14% |
| Corient Private Wealth LLCas of 31 Mar 2024 | 623.66k | 1.08% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 563.10k | 0.97% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 554.11k | 0.96% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
